34255953|t|Pediatric COVID-19 Delirium: Case Report of 2 Adolescents.
34255953|a|INTRODUCTION: Neurological complications of COVID-19, including delirium, are emerging in the adult population but have not been well described in pediatrics. CASE PRESENTATION: We report the cases of 2 adolescent males, ages 16 and 17, who presented with delirium secondary to an acute COVID-19 infection in the fall of 2020 at Children's Wisconsin in Milwaukee, Wisconsin. The foundation of our treatment strategy was the triad of alpha-2 agonists (clonidine, dexmedetomidine, guanfacine), antipsychotic agents (quetiapine, haloperidol, olanzapine), and melatonin. Discharge planning required involvement from inpatient psychiatry, case management, social work, and the family. Both patients showed improvement after several weeks. DISCUSSION: We believe these are the first reported cases of COVID-19-associated delirium in children outside of multisystem inflammatory syndrome in children (MIS-C). CONCLUSION: Pediatric COVID-19 delirium is a new manifestation of the COVID-19 disease. Treatment guidelines are emerging and lessons regarding therapies and discharge considerations are described in these 2 unique cases.
34255953	0	27	Pediatric COVID-19 Delirium	Disease	MESH:D000086382
34255953	73	99	Neurological complications	Disease	MESH:D002493
34255953	103	111	COVID-19	Disease	MESH:D000086382
34255953	123	131	delirium	Disease	MESH:D003693
34255953	315	323	delirium	Disease	MESH:D003693
34255953	346	364	COVID-19 infection	Disease	MESH:D000086382
34255953	492	499	alpha-2	Gene	170589
34255953	510	519	clonidine	Chemical	MESH:D003000
34255953	521	536	dexmedetomidine	Chemical	MESH:D020927
34255953	538	548	guanfacine	Chemical	MESH:D016316
34255953	573	583	quetiapine	Chemical	MESH:D000069348
34255953	585	596	haloperidol	Chemical	MESH:D006220
34255953	598	608	olanzapine	Chemical	MESH:D000077152
34255953	615	624	melatonin	Chemical	MESH:D008550
34255953	671	680	inpatient	Disease	
34255953	744	752	patients	Species	9606
34255953	854	862	COVID-19	Disease	MESH:D000086382
34255953	874	882	delirium	Disease	MESH:D003693
34255953	906	939	multisystem inflammatory syndrome	Disease	MESH:C000705967
34255953	973	1000	Pediatric COVID-19 delirium	Disease	MESH:D000086382
34255953	1031	1047	COVID-19 disease	Disease	MESH:D000086382
34255953	Cotreatment	MESH:D000069348	MESH:D006220
34255953	Cotreatment	MESH:D000069348	MESH:D008550
34255953	Negative_Correlation	MESH:D020927	MESH:D003693
34255953	Negative_Correlation	MESH:D008550	MESH:D003693
34255953	Negative_Correlation	MESH:D016316	170589
34255953	Negative_Correlation	MESH:D000069348	MESH:D003693
34255953	Negative_Correlation	MESH:D008550	MESH:D000086382
34255953	Cotreatment	MESH:D000077152	MESH:D006220
34255953	Cotreatment	MESH:D000077152	MESH:D008550
34255953	Negative_Correlation	MESH:D000069348	MESH:D000086382
34255953	Negative_Correlation	MESH:D003000	MESH:D000086382
34255953	Negative_Correlation	MESH:D003000	MESH:D003693
34255953	Positive_Correlation	MESH:D003000	170589
34255953	Negative_Correlation	MESH:D000077152	MESH:D003693
34255953	Negative_Correlation	MESH:D008550	170589
34255953	Cotreatment	MESH:D008550	MESH:D016316
34255953	Negative_Correlation	MESH:D020927	MESH:D000086382
34255953	Negative_Correlation	MESH:D006220	MESH:D000086382
34255953	Negative_Correlation	MESH:D006220	MESH:D003693
34255953	Negative_Correlation	MESH:D000077152	MESH:D000086382
34255953	Cotreatment	MESH:D006220	MESH:D008550
34255953	Cotreatment	MESH:D003000	MESH:D016316
34255953	Cotreatment	MESH:D003000	MESH:D008550
34255953	Positive_Correlation	MESH:D020927	170589
34255953	Negative_Correlation	MESH:D016316	MESH:D003693
34255953	Cotreatment	MESH:D008550	MESH:D020927

